GlassScriptPhysician profile
Amy Whitt
NPI 1851981229
$2,530.93
in general payments reported to CMS, 2019-2025
35 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $649 · 2022: $660 · 2023: $727 · 2024: $256 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $424.40 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $218.90 | 2022-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $178.28 | 2023 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $163.36 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $156.24 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $151.42 | 2024-2025 | Dysport |
| Boston Scientific Corporation | $130.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $87.78 | 2021 | |
| Pfizer INC. | $58.91 | 2021-2023 | |
| Celgene Corporation | $51.51 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $47.37 | 2023 | Assure Wcd |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $44.09 | 2023 | Caplyta |
| Exact Sciences Corporation | $42.79 | 2023 | Cologuard Collection Kit |
| Aquestive Therapeutics, INC. | $42.76 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $38.53 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $38.01 | 2023 | Trintellix |
| Neurocrine Biosciences, INC. | $37.65 | 2023 | Ingrezza |
| Amgen INC. | $36.70 | 2021 | |
| Alkermes, INC. | $29.29 | 2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $27.02 | 2023 | Auvelity |
| Biogen, INC. | $26.59 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.13 | 2022 | |
| Dexcom, INC. | $23.86 | 2023 | Dexcom G6 Transmitter |
| Upsher-Smith Laboratories LLC | $21.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.97 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $20.41 | 2021 | |
| Lilly USA, LLC | $20.16 | 2021 | |
| Neurelis, INC. | $18.72 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.64 | 2021 | |
| Grt US Holding, INC. | $16.83 | 2021 | |
| Novo Nordisk INC | $13.90 | 2023 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $13.75 | 2021 | |
| Allergan, INC. | $12.96 | 2021 | |
| Ucb, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Whitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.